INSP250117P370000
- 0.00
- 0.000.00%
Inspire Medical Systems Newsroom
KeyBanc Maintains Inspire Medical Systems(INSP.US) With Buy Rating, Announces Target Price $234
Inspire Medical Systems Analyst Ratings
Stifel Maintains Inspire Medical Systems(INSP.US) With Hold Rating, Maintains Target Price $190
Wells Fargo Maintains Inspire Medical Systems(INSP.US) With Hold Rating, Maintains Target Price $198
Stifel Maintains Inspire Medical Systems(INSP.US) With Hold Rating, Announces Target Price $190
Lake Street Maintains Inspire Medical Systems(INSP.US) With Buy Rating, Maintains Target Price $270
RBC Capital Maintains Inspire Medical Systems(INSP.US) With Buy Rating, Maintains Target Price $260
Piper Sandler Maintains Inspire Medical Systems(INSP.US) With Buy Rating, Maintains Target Price $260
Analysts Are Bullish on These Healthcare Stocks: Inspire Medical Systems (INSP), UnitedHealth (UNH)
Truist Financial Maintains Inspire Medical Systems(INSP.US) With Buy Rating
A Quick Look at Today's Ratings for Inspire Medical Systems(INSP.US), With a Forecast Between $230 to $270
Positive Growth Prospects Reinforce Buy Rating for Inspire Medical Systems
RBC Capital Maintains Inspire Medical Systems(INSP.US) With Buy Rating, Maintains Target Price $260
BofA Securities Maintains Inspire Medical Systems(INSP.US) With Buy Rating, Maintains Target Price $255
Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS), Denali Therapeutics (DNLI) and Inspire Medical Systems (INSP)
Oppenheimer Maintains Inspire Medical Systems(INSP.US) With Hold Rating
Hold Rating on Inspire Medical Systems Amid FDA Approval of Tirzepatide for OSA
Wells Fargo Maintains Inspire Medical Systems(INSP.US) With Hold Rating, Maintains Target Price $198
Wells Fargo Maintains Inspire Medical Systems(INSP.US) With Hold Rating, Maintains Target Price $198
Inspire Medical Systems: Balancing Growth Prospects and Market Challenges – A Hold Rating by Larry Biegelsen